(FM) Medicina Nuclear
Departamento académico
Université de Genève
Ginebra, SuizaPublicaciones en colaboración con investigadores/as de Université de Genève (14)
2020
-
Amyloid-PET and 18F-FDG-PET in the diagnostic investigation of Alzheimer's disease and other dementias
The Lancet Neurology, Vol. 19, Núm. 11, pp. 951-962
-
COVID-19 and the brain: impact on nuclear medicine in neurology
European Journal of Nuclear Medicine and Molecular Imaging
-
EANM practice guideline/SNMMI procedure standard for dopaminergic imaging in Parkinsonian syndromes 1.0
European Journal of Nuclear Medicine and Molecular Imaging, Vol. 47, Núm. 8, pp. 1885-1912
-
Proven validity and management impact of amyloid imaging in Alzheimer’s disease—repetita juvant
European Journal of Nuclear Medicine and Molecular Imaging
2019
-
Semi-quantification and grading of amyloid PET: A project of the European Alzheimer's Disease Consortium (EADC)
NeuroImage: Clinical, Vol. 23
2018
-
European Association of Nuclear Medicine and European Academy of Neurology recommendations for the use of brain 18 F-fluorodeoxyglucose positron emission tomography in neurodegenerative cognitive impairment and dementia: Delphi consensus
European Journal of Neurology, Vol. 25, Núm. 10, pp. 1201-1217
-
Assessing FDG-PET diagnostic accuracy studies to develop recommendations for clinical use in dementia
European Journal of Nuclear Medicine and Molecular Imaging, Vol. 45, Núm. 9, pp. 1470-1486
-
Automated assessment of FDG-PET for differential diagnosis in patients with neurodegenerative disorders
European Journal of Nuclear Medicine and Molecular Imaging, Vol. 45, Núm. 9, pp. 1557-1566
-
Clinical utility of FDG PET in Parkinson’s disease and atypical parkinsonism associated with dementia
European Journal of Nuclear Medicine and Molecular Imaging, Vol. 45, Núm. 9, pp. 1534-1545
-
Clinical utility of FDG-PET for the clinical diagnosis in MCI
European Journal of Nuclear Medicine and Molecular Imaging, Vol. 45, Núm. 9, pp. 1497-1508
-
Clinical utility of FDG-PET for the differential diagnosis among the main forms of dementia
European Journal of Nuclear Medicine and Molecular Imaging, Vol. 45, Núm. 9, pp. 1509-1525
-
Clinical utility of FDG-PET in amyotrophic lateral sclerosis and Huntington’s disease
European Journal of Nuclear Medicine and Molecular Imaging, Vol. 45, Núm. 9, pp. 1546-1556
-
Diagnostic utility of 18F-Fluorodeoxyglucose positron emission tomography (FDG-PET) in asymptomatic subjects at increased risk for Alzheimer’s disease
European Journal of Nuclear Medicine and Molecular Imaging, Vol. 45, Núm. 9, pp. 1487-1496
-
Diagnostic utility of FDG-PET in the differential diagnosis between different forms of primary progressive aphasia
European Journal of Nuclear Medicine and Molecular Imaging, Vol. 45, Núm. 9, pp. 1526-1533